SOLV or DHR: Which Is the Better Value Stock Right Now?

Core Insights - The article compares two Medical Services stocks, Solventum (SOLV) and Danaher (DHR), to determine which is the better undervalued investment option [1] Valuation Metrics - Solventum has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while Danaher has a Zacks Rank of 4 (Sell) [3] - SOLV's forward P/E ratio is 11.90, significantly lower than DHR's forward P/E of 27.20, suggesting SOLV is more attractively priced [5] - The PEG ratio for SOLV is 2.88, compared to DHR's PEG ratio of 3.22, indicating SOLV's expected earnings growth is more favorable [5] - SOLV's P/B ratio is 2.49, while DHR's P/B ratio is 2.9, further supporting SOLV's valuation advantage [6] - Based on these metrics, SOLV earns a Value grade of B, while DHR receives a Value grade of D, highlighting SOLV's superior valuation profile [6]